Prostate Cancer and Prostatic Diseases

Welcome to Prostate Cancer and Prostatic Diseases

Featured

The natural history of a delayed detectable PSA after radical prostatectomy

Julie A. Szymaniak
Samuel L. Washington III
Peter R. Carroll
ArticleOpen Access10 Feb 2023
Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate

Giampaolo Siena
Francesco Sessa
Luca Cindolo
Brief Communication13 Jan 2023
Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number

Simone Albisinni
Romain Diamand
Editorial02 Feb 2023
Best of 2022 in prostate cancer and prostatic diseases

Cosimo De Nunzio
Riccardo Lombardo
Editorial04 Feb 2023

Current issue

The evolving standards of active surveillance monitoring

Peter C. Albertsen
Editorial09 Sept 2022
Racial disparities in treatment patterns for localized prostate cancer in an equal access system: What are we missing?

Fabio Crocerossa
M. Carmen Mir
Editorial15 Nov 2022
Re: Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?

Shangqing Ren
Dong Wang
Correspondence23 Jan 2022
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes

John R. Heard
Aurash Naser-Tavakolian
Michael Ahdoot
Review Article04 Mar 2022
Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature

Anna Maria Grimaldi
Marco Salvatore
Carlo Cavaliere
Review Article09 Mar 2022
The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

Alex Pozdnyakov
Roshini Kulanthaivelu
Ur Metser
Review Article19 Apr 2022

Contents

View all issues

Announcements

NEW COLLECTION: Working hard or hardly working?

Featuring the latest research published in Prostate Cancer and Prostatic Diseases (PCAN) in recent years relating to the link between physical activity and prostate cancer.
NEW COLLECTION: A healthy diet, a healthy prostate?

Featuring the latest research published in Prostate Cancer and Prostatic Diseases (PCAN) in recent years relating to the link between obesity and dietary factors with prostate cancer.
NEW COLLECTION: Disparities in diagnosis and management

In this collection we present papers from recent years by some of the top investigators within the field, highlighting recognized disparities in prostate cancer care, from screening to risk stratification and treatments employed in patient care pathways.
PCan is now on Instagram!

Interact with PCan like never before, and get the latest news and research delivered straight to your feed. Also on Twitter! @pcan_journal

Prostate Cancer and Prostatic Diseases is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Browse articles

Characterisation of cell lines derived from prostate cancer patients with localised disease

Leire Moya
Carina Walpole
Jyotsna Batra
ArticleOpen Access01 Jun 2023
Functional and oncological outcomes after radical prostatectomy in patients with history of surgery for lower urinary tract symptoms related to benign prostatic enlargement: A systematic review with meta-analysis

Massimiliano Creta
Celeste Manfredi
Ferdinando Fusco
Review Article27 May 2023
Guidelines for genetic testing in prostate cancer: a scoping review

Haitham Tuffaha
Kim Edmunds
Paul Scuffham
Review ArticleOpen Access18 May 2023
Enucleation of the prostate as retreatment for recurrent or residual benign prostatic obstruction: a systematic review and a meta-analysis

Nikolaos Pyrgidis
Ioannis Mykoniatis
Petros Sountoulides
Review Article16 May 2023
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis

Ronald Tutrone
Ben Lowentritt
Johan Skog
ArticleOpen Access16 May 2023
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer

Tahlia Scheinberg
Hui-Ming Lin
Lisa G. Horvath
ArticleOpen Access05 May 2023
15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer

Akshay Sood
Ralph Grauer
Mani Menon
Article04 May 2023
Disparities in prostate cancer diagnosis and management: recognizing that disparities exist at all junctures along the prostate cancer journey

Soroush Rais-Bahrami
Yao Zhu
Editorial28 Apr 2023
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading

Andrey Morozov
Mark Taratkin
Dmitry Enikeev
Review Article25 Apr 2023

The Editor of Prostate Cancer and Prostatic Diseases is delighted to share with you this Editor's Choice collection featuring some of the best research and reviews published in the journal in 2022. These papers showcase the breadth of scope and coverage that this journal consistently delivers to its readers.

Collection 27 Feb 2023

Trending - Altmetric

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.

Welcome to Prostate Cancer and Prostatic Diseases

Featured

The natural history of a delayed detectable PSA after radical prostatectomy

Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate

Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number

Best of 2022 in prostate cancer and prostatic diseases

Current issue

The evolving standards of active surveillance monitoring

Racial disparities in treatment patterns for localized prostate cancer in an equal access system: What are we missing?

Re: Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?

Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes

Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature

The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

Announcements

NEW COLLECTION: Working hard or hardly working?

NEW COLLECTION: A healthy diet, a healthy prostate?

NEW COLLECTION: Disparities in diagnosis and management

PCan is now on Instagram!

Browse articles

Characterisation of cell lines derived from prostate cancer patients with localised disease

Functional and oncological outcomes after radical prostatectomy in patients with history of surgery for lower urinary tract symptoms related to benign prostatic enlargement: A systematic review with meta-analysis

Guidelines for genetic testing in prostate cancer: a scoping review

Enucleation of the prostate as retreatment for recurrent or residual benign prostatic obstruction: a systematic review and a meta-analysis

ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer

15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer

Disparities in prostate cancer diagnosis and management: recognizing that disparities exist at all junctures along the prostate cancer journey

A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading

Collections

Editors Choice 2022

Trending - Altmetric

Search

Quick links

Featured

Announcements

Advertisement

Trending - Altmetric

ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL

Characterisation of cell lines derived from prostate cancer patients with localised disease

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

Search

Quick links